Incidence and Prognostic Value of NPM1 and FLT3 Gene Mutations in AML with Normal Karyotype
Dalia Nafea1, *, Mohammed Abdel Rahman2, Dominique Boris3, Christine Perot4, J.P. Laporte4, F. Isnard4, P. Coppo4, N.C. Gorin4
Identifiers and Pagination:Year: 2011
First Page: 14
Last Page: 20
Publisher Id: TOHJ-5-14
Article History:Received Date: 03/01/2011
Revision Received Date: 17/01/2011
Acceptance Date: 21/01/2011
Electronic publication date: 02/5/2011
Collection year: 2011
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
NPM1 belongs to a new category of genes that function both as oncogenes and tumor suppressor genes, depending on gene dosage, expression levels, interacting partners, and compartmentalization. Nucleophosmin mutations within exon 12 have been described as the most frequent acquired molecular abnormalities in adult and pediatric acute myeloid leukaemia (AML), mutation can be observed in nearly half of patients with a normal karyotype and is associated with a favorable outcome. NPM1 mutations are characterized by the aberrant cytoplasmic localization of NPM, the absence of CD34, involvement of several cell lineages myeloid, monocytic, erythroid and megakaryocytic but not lymphoid and a high frequency of FLT3-ITD mutation. We aimed to study the prevalence, association with Flt3 mutations, and prognostic impact of NPM1 exon-12 mutations in 71 AML patients with normal karyotype. We studied NPM1 and FLT3 by RT PCR. NPM1 gene mutation was detected among 34 patients (47.9%) and was associated with a high white blood cell count, involvement of the monocytic lineage, CD34 negativity, and high frequency of FLT3ITD. DFS and OS did not differ between mutated and unmutated NPM patients. Prospective studies are needed to confirm the definitive place of NPM mutation among patients with normal karyotype.